April 2026 Research Update

Studies this month add a practical picture of IL-1 blockers (anakinra and canakinumab) in FMF: access can be very uneven across countries, and symptom improvement is possible for some people but not guaranteed. Across these studies, the main message is that IL-1 blockers are part of the FMF treatment landscape, yet real-world availability and individual symptom response vary widely. This matters because it helps explain why two people with similar symptoms may have very different treatment options and experiences. [1] [2]

When IL-1 blockers were used for exertional leg pain (leg pain brought on by activity) in a small group of colchicine-resistant patients, about half reported improvement and average pain scores went down, but many still had ongoing pain. Quality of life scores improved in parallel, and people with more remaining pain tended to report worse quality of life while on treatment. The key point for patients is that this symptom may improve for some, but it can also persist even when inflammation-targeting medicines are used. [2]

Access to these medicines differed a lot across 39 countries, with some places having the drug available but not reimbursed, and many countries adding extra prescribing or reimbursement restrictions beyond guideline statements. Some national guidance documents matched older EULAR 2016 recommendations, but not all countries had a national guideline identified in this survey. In day-to-day life, this helps put policy barriers into context as a major part of the treatment story for colchicine-resistant FMF, separate from whether a medicine might help medically. [1]

For patients and caregivers, this month mainly adds understanding of what to expect around IL-1 blockers rather than proving a single clear outcome for everyone. The evidence about exertional leg pain comes from a small retrospective study, so it gives an early real-world signal that some people may feel better while others may not. The access study does not test health outcomes, but it does clarify why getting these medicines can depend heavily on where someone lives and what rules apply there, which can shape real options even when a drug exists. [1] [2]

Several clinical studies this month make FMF feel less like a single repeating "attack" pattern and more like a condition with important in-between signals, especially in children and adolescents. Exertional leg pain and subclinical inflammation (ongoing inflammation between attacks) both clustered with markers of more severe disease and certain gene variants. For patients, the overall picture is that ongoing symptoms or lab inflammation between attacks can carry information about disease burden, even if they are easy to dismiss as unrelated. [3] [4] [5]

In a large pediatric cohort, exertional leg pain was common and was linked with other joint or skin features and with signs of more severe FMF, including a higher frequency of M694V homozygosity and colchicine resistance. A smaller imaging study adds that some children with exertional leg pain showed measurable differences on ultrasound, such as thicker Achilles tendons and more small knee fluid collections that were often not obvious on exam. Taken together, these results suggest exertional leg pain can sometimes reflect underlying inflammation in muscles, tendons, or joints, rather than being only a general pain complaint. [3] [5]

Subclinical inflammation was reported in about 1 in 6 pediatric patients in one center, and it was more likely in those with earlier onset, longer disease duration, arthritis, higher severity scores, and biallelic exon 10 mutations. In that cohort, inflammatory markers normalized in some patients after colchicine dose adjustments, and many others required biologic therapies, with most then reaching normal inflammatory markers. The main takeaway is that "silent" inflammation between attacks was measurable in a sizable minority and was not random, but tended to cluster with higher-risk clinical features. [4]

This set of studies may matter now by helping families name and describe patterns that sometimes get overlooked, like exertional leg pain or inflammation that continues between attacks. The evidence is mostly observational, so it cannot prove what causes these findings, but it does clarify that they are common enough to study and often appear alongside more severe FMF features. What remains uncertain is how well these signs predict long-term outcomes for an individual child, and how best to track them over time, since the ultrasound and symptom studies were not designed to answer that. [3] [4] [5]

This month included studies aimed at improving how FMF is recognized and how future complications might be anticipated. One study suggests that broader genetic testing can uncover additional variants in people who seem to have FMF but do not show clear results on older, limited gene panels. Another study suggests that computer-based prediction models may help estimate amyloidosis risk using clinical and genetic features, with some models performing better than standard regression in this dataset. [6] [7]

In people clinically diagnosed with FMF who were negative or only single-variant positive on traditional MEFV testing, next-generation sequencing found additional genetic variants in about one-third of cases. This included missed MEFV variants and variants in other autoinflammatory genes, along with diverse symptoms and variable response to colchicine noted on clinical reevaluation. The practical meaning is that FMF-like illness can have more genetic variety than a limited test captures, which may help explain why some patients do not fit the typical picture. [6]

In a large retrospective cohort, machine learning models were tested for predicting FMF-associated amyloidosis, and a random forest model performed best in this dataset. The model highlighted factors such as M694V homozygosity, longer disease duration, muscle pain, a specific FMF skin rash (erysipelas-like erythema), and arthritis as important contributors to risk prediction. For patients, this adds to the idea that amyloidosis risk is connected to a recognizable cluster of disease features, although the study does not show that changing any single factor will change risk. [7]

For patients and caregivers, these studies mostly matter as "building better maps" rather than changing what should happen immediately. The genetic study suggests that broader testing can sometimes provide an explanation when older testing is unrevealing, but it also introduces uncertainty because some findings may be variants of unknown significance and may not clearly answer what is causing symptoms. The amyloidosis model study offers a structured way to combine information into a risk estimate, but it is based on one center's retrospective data and needs confirmation before it can be considered reliable across settings. [6] [7]

Two studies in adolescents suggest that menstrual-cycle symptoms and FMF symptoms can overlap, and the overlap can be confusing without careful attention to inflammation signs and symptom patterns. Menstruation was not a uniform trigger for true FMF attacks, and many symptoms around menstruation matched typical premenstrual syndrome (PMS) patterns. For patients, this helps explain why a period can feel like an FMF flare even when inflammatory signals are smaller than during a usual attack. [8] [9]

In one study, 38% of adolescents reported menstruation-triggered FMF attacks, but laboratory inflammation during menstruation rose only slightly and stayed lower than during typical attacks. Mood disturbances were much more common in the group reporting menstruation-triggered attacks, and many reported symptoms aligned with PMS or PMDD rather than clear FMF flares. This matters because it suggests that some "attack-like" experiences during menstruation may reflect menstrual symptom syndromes, FMF activity, or both. [8]

A separate comparison with healthy controls found that PMS frequency and severity were lower overall in the FMF group, but within FMF, higher PMS burden went along with more frequent attacks and higher disease activity scores. PMS-positive patients also had higher inflammatory markers and poorer colchicine adherence in this snapshot. The key point is not that PMS causes FMF activity, but that PMS burden and FMF burden can move together in some adolescents and may be linked to medication-taking patterns. [9]

This month mainly adds clarity for families trying to interpret symptoms around menstruation, especially in teens. The studies suggest it is possible to have significant menstrual-related symptoms that look like flares, and that inflammation levels during menstruation may be smaller than during typical FMF attacks, which could help with interpretation. What remains uncertain is how these findings apply across different ages and over time, since both studies were relatively small and cross-sectional. [8] [9]

This month also added early signals about what may be happening biologically in FMF, including small RNA regulators (microRNAs), pregnancy placental inflammation patterns, and changes seen in the eye's small blood vessels. These studies do not translate directly into new tests or treatments yet, but they help sketch where researchers are looking for explanations and future targets. For patients, the value is in building a more detailed understanding of inflammation pathways and possible body-wide effects of FMF. In the eye study, severe twisting of retinal vessels was seen more often in the FMF group than in controls (23.8% versus 2.3%), although the study does not establish what this finding means clinically. [10] [11] [12] [13] [14]

Human blood studies reported that certain microRNAs differed between FMF patients and healthy controls, with two decreased and one increased, alongside higher IL-36Ra (a natural blocker of IL-36 signaling). The authors interpreted this as a possible "push-pull" pattern where some anti-inflammatory regulators are lower while other anti-inflammatory signals rise. This matters because such patterns are the kind of clues that could someday support biomarkers, although this study does not show how well these measures track symptoms or predict outcomes. [10]

Lab and animal studies focused on miR-197-3p as a potential brake on the pyrin inflammasome pathway, which is central to FMF inflammation. In mouse immune cells, increasing miR-197-3p lowered IL-1beta release after pyrin activation, and in an FMF mouse model, microvesicles loaded with miR-197-3p reduced inflammatory signals and improved observed inflammation signs. The meaning for patients is future-facing: these are early proof-of-concept steps and do not predict whether a similar approach would be safe or effective in people. [11] [12]

In a small retrospective pregnancy study, placentas from FMF-affected pregnancies showed more inflammatory and blood-flow related changes than controls, and exploratory comparisons suggested fewer of some abnormalities among colchicine-exposed pregnancies. The study also reported perinatal outcomes such as preterm delivery averages and NICU admissions, but the sample was very small, so firm conclusions are not possible. This adds an early signal that inflammation may leave a footprint in the placenta in some FMF pregnancies, which could be a research direction for larger studies. [13]

A separate case-control report in children and young adults found severe twisting (tortuosity) of retinal blood vessels without changes in vessel diameter. The study does not establish what this means for vision or whether it relates to disease activity. For patients, it is a reminder that researchers are examining subtle blood-vessel changes in FMF, but this is not yet a routine part of care. [14]

For patients, this group is mainly early research that may matter later if confirmed, rather than something that changes monitoring or treatment now. The microRNA findings and mouse experiments point toward specific inflammation control knobs that researchers may be able to target, but they are not validated tools for predicting flares or choosing a therapy. The pregnancy and retinal studies raise questions about how FMF-related inflammation might show up outside classic attacks, but bigger studies are needed to know how common these findings are and what they mean for long-term outcomes. [10] [11] [12] [13] [14]

One case report described an unusual pairing of FMF and pleural mesothelioma in a person without asbestos exposure, raising a question rather than answering it. The authors noted frequent episodes of serositis and poor colchicine adherence, and discussed whether long-term serosal inflammation could be relevant. For patients, this is best read as a prompt for further research, not evidence that FMF commonly leads to this cancer. [15]

In this single patient, pleural biopsy confirmed epithelioid pleural mesothelioma, and after surgery and chemotherapy the condition was reported as stable at 10 months. Because it is one person, it cannot show risk levels or prove a connection to FMF. Its contribution is simply that it documents a rare scenario that could be tracked in larger registries in the future. [15]

This evidence is limited to a single person, so it is mainly for research awareness rather than personal risk prediction. It helps clarify that researchers are paying attention to long-term inflammation in FMF as a possible factor in rare outcomes, but it remains unknown whether there is any true increased risk and, if so, for whom. Nothing in this report can be used to estimate what will happen to other patients. [15]